Related references
Note: Only part of the references are listed.Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort
Segolene Brichler et al.
JOURNAL OF VIRAL HEPATITIS (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B
Mandana Khalili et al.
DIABETES CARE (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Association of High Body Mass Index and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection: A Korean Population-Based Cohort Study
Kyuwoong Kim et al.
JAMA ONCOLOGY (2018)
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Vincent Wai-Sun Wong et al.
JOURNAL OF HEPATOLOGY (2018)
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B
Grace Lai-Hung Wong et al.
JOURNAL OF HEPATOLOGY (2018)
Nonalcoholic Fatty Liver Disease
Xiao Jing Wang et al.
ANNALS OF INTERNAL MEDICINE (2018)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy
Ira M. Jacobson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Weight Loss Results in Significant Improvements in Quality of Life for Patients With Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study
Elliot B. Tapper et al.
HEPATOLOGY (2016)
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients
W. Ray Kim et al.
JOURNAL OF HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
Melina Arnold et al.
LANCET ONCOLOGY (2015)
Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy
Cheng-Chao Liang et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection
Philip R. Spradling et al.
JOURNAL OF HEPATOLOGY (2014)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years
G. L. -H. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C
Yo-hei Aoki et al.
HEPATOLOGY RESEARCH (2011)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
Body-Mass Index and Progression of Hepatitis B: A Population-Based Cohort Study in Men
Ming-Whei Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis
Chantal A. Rivera et al.
JOURNAL OF HEPATOLOGY (2007)
Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C
P. H. Thurairajah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
Primary care: Evaluation of abnormal liver-enzyme results in asymptomatic patients.
DS Pratt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
